Hosted on MSN1mon
Leerink Partners Downgrades 10x Genomics (TXG)
Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from Outperform to Market Perform. Analyst Price Forecast Suggests 71.13% Upside ...
Nasdaq28d
Insider Sale: Chief Executive Officer of $TXG Sells 7,942 Shares
Serge Saxonov, the Chief Executive Officer of $TXG, sold 7,942 shares of the company on 02-28-2025 for an estimated $84,393. We received data on the trade from a ...
Nasdaq1mon
Insider Purchase: Director at $TXG Buys 40,000 Shares
ALAN MATEO, a director at $TXG, bought 40,000 shares of the company on 02-21-2025 for an estimated $445,572. This trade was reported by Quiver Quantitative using data ...